Introduction: Breast cancer is the most common cancer in the female population worldwide. Its incidence and associated mortality have increased in recent decades due to its association with risk factors, better diagnostic methods and increased case records. Understanding recent patterns of morbidity and mortality is fundamental to evaluating the effectiveness of public health interventions and identifying gaps. Objectives: To assess the epidemiological and regional profile of breast cancer distribution in Brazil between 2020 and 2024. Methods: This is a descriptive observational study, with a quantitative approach, carried out through the collection of secondary data obtained from the Department of Informatics of the Unified Health System (DATASUS), addressing the epidemiological profile of breast cancer morbidity and mortality in Brazil by region in the period between 2020 and 2024. The data was collected in April 2025 and arranged and analyzed in Microsoft Excel 2016 spreadsheets and analyzed using simple descriptive statistics, evaluating the variables of gender, ethnicity, age group, deaths and mortality rate. Results: Between 2020 and 2024, approximately 394,756 cases were recorded, and it was observed that the southeast region had the highest number in all the years evaluated, with a total of 190,914 (48.36%) cases. The North had the lowest number of cases, with 14,052 (3.55%). There was a progression in the number of absolute cases identified over the assessed period of +36%. During this period, the ethnic groups most affected were white with 173,060 (43.83%) and brown with 166,092 (42.07%) of the cases. It should be noted that the predominance of cases was between the ages of 30-69, with 289,073 (73.22%) cases. The average hospitalization time was 3 days, with the northern region having the highest average of 4.2 days and the lowest average in the southern region with 2.5%. The number of deaths from breast cancer in the same period was 30,964, with an overall death rate of 7.84%, with the highest relative mortality rate in the North (9.86%) and the lowest in the Northeast (6.93%), with a predominance of deaths in the Southeast with a total of 15,980 (51.6%), and the lowest number in the North, with 1,385 (4.47%). Conclusion: Breast cancer is a clinical condition with a discreet symptomatology that requires constant and adequate screening as a strategy for preventing this pathology. This study showed significant growth patterns in the prevalence of hospital morbidity due to malignant breast neoplasia, which favors earlier interventions and better follow-up of these patients. The large number of patients affected by this condition from a young age justifies early screening. The regional differences in mortality rates and length of hospitalization may be due to differences in the infrastructure for screening and medical care, as well as differences in the population of each region. This study emphasizes the importance of early screening and highlights the importance of more specific studies for each macro-region.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
